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Abstract
Sclerotium rolfsii lectin (SRL) isolated from the phytopathogenic fungus Sclerotium rolfsii has exquisite binding specificity
towards O-linked, Thomsen-Freidenreich (Galb1-3GalNAca1-Ser/Thr, TF) associated glycans. This study investigated the
influence of SRL on proliferation of human breast cancer cells (MCF-7 and ZR-75), non-tumorigenic breast epithelial cells
(MCF-10A) and normal mammary epithelial cells (HMECs). SRL caused marked, dose-dependent, inhibition of proliferation of
MCF-7 and ZR-75 cells but only weak inhibition of proliferation of non-tumorigenic MCF-10A and HMEC cells. The inhibitory
effect of SRL on cancer cell proliferation was shown to be a consequence of SRL cell surface binding and subsequent
induction of cellular apoptosis, an effect that was largely prevented by the presence of inhibitors against caspases -3, -8, or -
9. Lectin histochemistry using biotin-labelled SRL showed little binding of SRL to normal human breast tissue but intense
binding to cancerous tissues. In conclusion, SRL inhibits the growth of human breast cancer cells via induction of cell
apoptosis but has substantially less effect on normal epithelial cells. As a lectin that binds specifically to a cancer-associated
glycan, has potential to be developed as an anti-cancer agent.
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Introduction
Lectins are a group of highly diverse proteins of non-immune
origin ubiquitously distributed in plants, animals and fungi. A
lectin contains at least one non-catalytic domain that selectively
recognizes and reversibly binds to specific glycans [1]. Some
lectins can recognize tumour associated-glycans and are therefore
useful tools to differentiate malignant from benign tumours and
also to study cancer-associated glycosylation changes [2]. Aberrant
glycosylation in cancerous and pre-cancerous tissues is common
and this is exemplified by incomplete synthesis of carbohydrate
chains, allowing higher expression of precursor carbohydrate
moieties, such as the oncofetal Thomsen-Freidenreich [CD176:
Galb1, 3GalNAca-O-Ser/Thr, TF] and Tn [CD175: GalNAca-
O-Ser/Thr] antigens whose expressions are correlated with tumor
progression and metastasis [3,4,5]. Recent studies have shown the
exclusive expression of N-glycolylneuraminic acid (Neu5Gc) on
glycoproteins and gangliosides in human melanoma, colon,
retinoblastoma and breast cancers but not in normal tissues [6],
another example is that of a monosialicganglioside, N-glycolyl
GM3, which is not expressed in normal human tissues, but is
detected in human breast tumors [7]. Hence these tumour-
associated glycans are gaining significance as attractive candidates
for the development of anti-cancer strategies [8].
Sclerotium rolfsii, a soil-borne phyto-pathogenic fungus, secretes
a developmentally regulated lectin [9], SRL, which has been
shown previously to recognizes the oncofetal TF antigen and its
derivatives [10]. The crystal structure of SRL, both in its free form
and as complex with N-acetyl-D-galactosamine (GalNAc) and N-
acetyl-D-glucosamine (GlcNAc) has been determined at 1.1 A˚,
2.0 A˚ and 1.7 A˚ resolutions, showing the presence of two
carbohydrate binding-sites per SRL monomer. The primary
carbohydrate-binding site of SRL recognizes the TF disaccharide
and N-acetyl-D-galactosamine and the secondary binding site
recognizes N-acetyl-D-glucosamine [11]. Our previous studies
have shown that SRL binds to the surface of cancer cells and
inhibits the growth of human colon and ovarian cancer cells in
vitro and suppresses growth of colon xenografts in vivo [12,13].
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The present study investigated the effect of SRL on proliferation of
human breast cancer (MCF-7 and ZR-75), which are known to
express Thomsen–Friedenreich (T/TF) antigen and its derivatives
due to reduced expression of core-2 b1,6-GlcNAc-transferase [14]
and normal mammary (HMECs and MCF-10A) epithelial cells in




BSA (Bovine serum albumin), bovine sub maxillary mucin and
Calcein AM (Acetoxy Methyl) fluorescent dye, were obtained from
Sigma Chemical Co. (St. Louis, USA). FCS (Fetal calf serum) was
from Gibco Invitrogen (Paisley, UK), 3-3’ diaminobenzidine
chromogen/H2O2 substrate in buffered solution (pH 7.5) (DAB
kit) was obtained from Bangalore Genei, Bangalore, India.
Hybond poly vinylene diflurodine (PVDF) membrane and MTT
[3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
were obtained from GE Life Sciences (Pittsburgh, PA, USA).
Caspase Glo3/7 Assay kit was procured from Promega, Madison,
USA and caspase inhibitors, Caspase-3 z-VAD (OMe) (N-
Benzyloxycarbonyl-Val-Ala-Asp), caspase-8 z-IETD (Ile-Glu(O-
Me)-Thr-Asp(O-Me)), caspase-9 Z-LEHD (Leu-Glu-(OMe)-Thr-
Asp-(OMe)), were from Calbiochem, Nottingham, UK. Annexin-
V detection kit was procured from Biovision (USA). Antibodies
against active caspase-3 were from Epitomics (USA). Polyclonal
mouse antibodies to FasL (Fas Ligand), FADD (Fas-associated
death domain), Caspase-8, -9, t-BID (Truncated BH3 interacting-
domain death agonist) were procured from Santa Cruz Biotech-
nology, California, USA. Mouse polyclonal PARP (Poly ADP
ribose polymerase) antibody was from PIERCE, Barrington, USA.
Species-specific HRP (Horseradish peroxidise)-labelled secondary
antibodies were procured from Bio Rad, Hercules, USA. aBSM
(Asialo bovine sub maxillary mucin) and asialo glycophorin A was
prepared by acid hydrolysis of bovine sub maxillary mucin and
glycophorin A, according to the method of R.G. Spiro [15].
Cell culture
The human breast cancer cells MCF-7 and ZR-75 were
obtained from the European Cell Culture Collection via the Public
Health Laboratory Service (Porton Down, Wiltshire, UK) and
cultured in DMEM (Dulbecco’s modified Eagle’s medium)
Figure 1. SRL histochemistry to normal and cancerous human breast tissues. SRL histochemistry was performed in human breast (normal,
primary cancer and metastatic) tissue samples. SRL shows weak binding to normal human breast tissues but strong binding to primary cancer and
metastatic breast tissues. All the images were obtained with 100X magnification. Arrows point to SRL binding to apical surface of the secretory gland
epithelia. Representative images of both Haematoxylin-Eosin and Biotin-SRL staining are shown. SRL binding was evaluated through optical analysis
by measuring the mean area of stained cells scored arbitrarily as intense (+++), moderate (++), light (+) and no staining (2).
doi:10.1371/journal.pone.0110107.g001
Effect of SRL on Normal and Breast Cancer Cells
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supplemented with 10% FCS, 100 units/ml penicillin, 100 mg/ml
streptomycin (complete DMEM) at 37uC in 5% CO2. Human
Mammary Epithelial Cells (HMEC) derived from reduction
mammoplasty were purchased from Lonza (Walkersville, MD,
USA) and were cultured in Mammary epithelial basal media
(MEBM) containing necessary supplements of Bovine pituitary
extract (BPE), Human epidermal growth factor (hEGF), Human
insulin, Hydrocortisone, Gentamicin (30 mg/ml) and Amphoter-
icin (15 mg/ml). Non-tumorigenic MCF-10A cells derived from
human fibrocystic mammary tissue were a kind gift from Dr.
Milind Viadya and were cultured in DMEM-F12 (1:1) complete
media containing necessary supplements of EGF (20 ng/ml),
Hydrocortisone (0.5 mg/ml), Cholera toxin (100 ng/ml), Insulin
(10 mg/ml), penicillin (100 units/ml) and streptomycin (100 mg/
ml) and maintained at 37uC in 5% CO2.
SRL conjugation with FITC, biotin and Sepharose-4B
SRL from the sclerotial bodies of the fungus was purified as
described previously [6]. SRL was conjugated with FITC
(Fluorescein isothiocyanate) by the method described by Goldman
et al. [16]. Biotinylation of SRL was carried out according to the
method of Duk et al. [17]. SRL was conjugated to Sepharose-4B
by the method of March et al. [18]. SRL conjugated Sepharose-4B
was suspended in TBS (25 mM Tris buffered saline, pH 7.5) and
stored at 4uC.
Lectin Histochemistry
Human breast tissue samples (normal, primary and metastatic
cancer tissues) used in the study were procured from S. L. Raheja
Hospital, Mumbai, India, consent was not obtained from donors
for the use of tissue and Institutional Review Board of S. L. Raheja
Hospital, Mumbai, India (IRB No. 08/2009) has approved the
method of consent, prior to conducting this study. Tissue samples
Figure 2. SRL inhibits proliferation of human breast cancer cells. (A). SRL causes dose-dependent inhibition of human breast cancer MCF-7
and ZR-75 cell proliferation. The cells were incubated with or without different concentrations of SRL for 72 h. SRL-mediated cell growth inhibition is
prevented by the presence of TF-expressing glycoprotein: MCF-7and ZR-75 cells were incubated with or without 20 mg/ml SRL in the presence of
100 mg/ml asialo bovine submaxillarymucin (aBSM) for 72 h. SRL caused time-dependent inhibition of MCF-7 cell proliferation. (B). The MCF-7 cells
were incubated with or without different concentrations of SRL, BSA (40 mg/ml) and TBS for 24, 48 and 72 h before cell proliferation was assessed.
Data represent Mean 6SD of triplicate determinations from three different assessments. *p,0.05; ***p,0.001.
doi:10.1371/journal.pone.0110107.g002
Effect of SRL on Normal and Breast Cancer Cells
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e110107
were obtained during surgery, fixed in buffered formalin and
embedded in paraffin for routine pathological examination by
Haematoxylin-Eosin staining. All the samples used for histochem-
istry were retrospectively retrieved from the archives where
samples were stored with appropriate histopathology numbers.
Since there was no clinical intervention in the approved study, the
ethic committee granted permission to retrieve paraffin blocks and
slides for analysis. None of the authors were involved in sample
collection and they did not have access for sample collection.
Lectin histochemistry using biotinylated-SRL (20 mg/ml) was
carried out on 5 mm tissue sections as described by Boland et al
[19]. SRL binding was evaluated by optical analysis and scored by
measuring the mean area of stained cells and expressed as intense
(+++), moderate (++), light (+) and no binding (2).
Assessment of cell proliferation
Sub-confluent MCF-7 and ZR-75 cells were seeded at 46104
cells/ml in 96 well plates in DMEM complete medium for 48 h.
The medium was replaced with serum-free DMEM containing
0.5% BSA (w/v) and the cells were incubated with various
concentrations of SRL (0–40 mg/ml), BSA (40 mg/ml) and TBS
for different time intervals (24, 48 and 72 h) in the presence or
absence of TF-expressing glycoproteins (asialo bovine submaxil-
lary mucin and asialoglycophorin-A). MCF-7 cells were treated
with SRL (20 and 40 mg/ml with a hemagglutination titre of 128
and 256 respectively) and Sepharose-conjugated SRL with
equivalent hemagglutination titre of 128 and 256 at 37uC for
72 h. In another experiment MCF-7 cells were treated with SRL
for 48 h with or without pre-incubation with Pan caspase-inhibitor
[Z-VAD (OMe), 50 mM]. The cells processed as above were then
labelled with 10 mg/ml Calcein AM at 37uC for 30 min in 5%
CO2, lysed with 100 ml lysis buffer (50 mM Tris-HCl, pH 6.8,
containing 5% SDS (Sodium dodecyl sulphate) and 2% mercap-
toethanol) and the fluorescent intensity was read using a Tecan i-
200 microplate reader with excitation wavelength of 485 nm and
emission wavelength of 535 nm.
Sub-confluent HMECs and MCF-10A cells were seeded at
46104 cells/ml in 96 well plates in MEBM or DMEM-F12 media
respectively with appropriate supplements for 48 h. In the case of
MCF-10A the media were then replaced with serum-free
supplemented DMEM-F12 containing 0.5% BSA (w/v) and both
cell lines were then incubated with various concentrations of SRL
Figure 3. Effect of SRL on proliferation of non-tumorigenic and normal human breast epithelial cells. (A and B) Non-tumorigenic MCF-
10A and normal HMECs were incubated with different concentrations of SRL in serum free media for different time intervals (24, 48 and 72 h for MCF-
10A) and 48 h (HMECs). Cell proliferation was measured using Calcein AM and MTT for MCF-10A and HMEC respectively. The experiments were
carried out in triplicate, and the data were expressed as Mean 6 SD percentage of control. *p,0.05; ***p,0.001.
doi:10.1371/journal.pone.0110107.g003
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for different time intervals (24, 48 and 72 h). MCF10A cells were
labeled with Calcein AM and the fluorescent intensity was
measured as described above. HMECs viability was measured
by MTT (3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bro-
mide) assay. Briefly, HMECs were cultured in MEBM for 48 h
and incubated with various concentrations of SRL for 48 h.
Following incubation, 10 ml of MTT (5 mg/ml) was added to each
well followed by lysis of the cells in 100 ml of 10% SDS in 0.01 N
HCl and absorbance was measured at 570 nm, with reference
wavelength of 640 nm, using ELISA plate reader. Percentage
viable cell number was calculated, with respect to controls
considered as 100%.
Assessment of SRL cell surface binding
MCF-7 and HMEC cells (0.56106 cells/ml) were grown on
cover slips in DMEM and MEBM media respectively and
incubated with 3% BSA for 1 h at 4uC. Cells were washed with
PBS (Phosphate buffered saline) and incubated with FITC-SRL
(2 mg/ml) for 1 h at 4uC. The cells were washed thrice with PBS
and fixed with 2% para-formaldehyde for 10 min. The cells were
counter-stained with DAPI (4’,6-diamidino-2-phenylindole) before
visualization using a Confocal Laser scanning Microscope (Zeiss
LSM 510, Germany) equipped with 488 nm and 560 nm Argon
lasers.
Assessment of cellular apoptosis
Detection of Apoptosis by Annexin-V/PI staining. MCF-
7 cells (0.56106) cultured in 6 well plates were treated with or
without SRL (20 mg/ml) for 24, 36, and 48 h in serum free media
and then harvested by gentle trypsinization, washed with PBS and
resuspended in binding buffer from Biovision Annexin–V kit. The
resuspended cells were incubated with 5 ml FITC Annexin-V
(Biovision) and 5 ml PI (Propidium Iodide) for 5 min at 37uC in the
dark before analysis by flow cytometry (FACS Calibur, BD). The
percentages of cells positive for Annexin V, PI alone and both
Annexin V and PI were calculated by dot blot analysis using Cell
Quest Pro software (BD Biosciences).
Caspase 3/7 activity. MCF-7 cells were cultured in 96 well
plates at 46104 cells/ml in DMEM complete media for 48 h
before introduction of caspases inhibitors (50 mM) against caspase-
3(z-VAD-(OMe)), caspase-8 (z-IETD) or caspase-9 (z-LEHD) in
serum-free media followed by addition of SRL (20 mg/ml) for
48 h. Cell apoptosis was then determined by measuring caspase-
Figure 4. Sepharose-conjugated SRL induced growth inhibition of breast cancer cells. (A) SRL shows strong binding to MCF-7 cells and
very weak binding to (B) HMEC. (C) MCF-7 cells were incubated without or with SRL or Sepharose-SRL (C-SRL), at equivalent concentrations to SRL
with 128 and 256 hemagglutination units (HAU) activity for 72 h before the cell proliferation was assessed by Calcein AM. Data represent Mean 6SD
of triplicateexperiments. *** p,0.0001 when compared to control.
doi:10.1371/journal.pone.0110107.g004
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3/7 activity using Caspase Glo3/7 assay according to manufac-
turer’s instructions.
In another experiment MCF-10A cells were cultured in 96 well
plates at 46104 cells/ml in DMEM-F12 complete media for 48 h
before treatment with SRL (20 mg/ml) for 48 h. Cell apoptosis was
then determined by measuring caspase-3/7 activity using Caspase
Glo-3/7 assay according to manufacturer’s instructions.
In another experiment MCF-7 cells (0.56106) were grown on
cover slips in 6 well plates in DMEM complete media and
incubated with SRL 20 mg/ml for 36 h followed by staining with
FITC-SRL (2 mg/ml), Anti-active caspase-3 primary antibody
followed by pycoerythrin labelled secondary antibody and images
were observed by fluorescence microscopy.
Cell cycle analysis. MCF-7 cells (0.56106) were cultured in
6 well plate and treated with or without SRL (20 mg/ml) for 24,
36, and 48 h in serum-free media before harvesting by gentle
trypsinization, followed by washing with PBS, fixation in 70%
chilled ethanol and were then kept at220uC until further analysis.
Cells were washed and rehydrated in PBS, treated with 50 ml
Ribonuclease A (5 mg/ml in PBS, DNase free) for 10 min at room
temperature and stained with Propidium Iodide (50 mg/ml in PBS)
for 30 min at 37uC. Data acquisition was performed using the FL-
2A channel of the Flow Cytometer (FACS Calibur, BD) and was
analyzed by Mod Fit LT mac2.0 software (Verity) for the
distribution of cells in different phases.
Western Blotting. MCF-7 cells were incubated with or
without SRL (20 mg/ml) in serum-free media at 37uC for 24, 36 or
48 h. The cells were harvested by gentle trypsinization and lysed
using RIPA lysis buffer (120 mM NaCl, 1.0% Triton X-100,
20 mM Tris–HCl, pH 7.5, 100% glycerol, 2 mM EDTA, and
protease inhibitor cocktail, Roche, Germany). Total protein was
fractionated on SDS-PAGE and blotted onto Hybond polyviny-
lidene difluoride membranes. After blocking with 5% BSA the
blots were incubated with antibodies against FasL, FADD,
Caspase-8, tBID, caspase -9, active caspase-3, or PARP for 4 h
followed by incubation for 1 h with the species specific HRP
conjugated secondary antibodies (1:1000). The blots were devel-
oped and visualized by chemiluminescence using ECL plus
substrate (Amersham, GE). The blots were stripped and reprobed
for b-actin for protein loading control.
Statistical analysis
Each experiment was performed at least three times, and each
time in triplicate. Results were analyzed by one-way ANOVA
followed by ‘Newman-Keuls’ multiple comparisons using Stat
Direct software and data considered significant (*) when P#0.05.
Results
SRL shows strong binding to cancer tissues
SRL showed intense staining in primary and metastatic human
breast cancer tissues and relatively light staining in the normal
tissues (Figure 1). This is in keeping with the binding specificity of
SRL to the TF-related glycans which are known to be over-
expressed in cancerous and in particular metastatic tissues.
Figure 5. SRL induces cell apoptosis. (A) Annexin V cell surface binding in MCF-7 cells after incubation with SRL (20 mg/ml) for 24, 36 or 48 h.
Percentages of cells in each quadrant are shown as inserts. The graph indicates percentage of the cell population in different phases. (B) Effect of SRL
on cell cycle. MCF-7 cells were exposed to SRL (20 mg/ml) for 24, 36 and 48 h before the cellswere stained with propidium iodide and DNA content
was measured by flow cytometry. The graph indicates percentage of cells in subG1, G1, S, and G2–M phases of the cell cycle.
doi:10.1371/journal.pone.0110107.g005
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SRL shows strong inhibition of proliferation in human
breast cancer cells
The presence of SRL was found to cause a dose- and time-
dependent inhibition of proliferation of human breast cancer
MCF-7 and ZR-75 cells. At 20 and 40 mg/ml SRL caused
49.566.5% (P,0.0001) and 61.362.7% (P,0.0001) growth
inhibition in MCF-7 cells after 48 h and 78.163.8% (P,0.0001)
and 80.667.6% (P,0.0001) inhibition after 72 h, whereas the
presence of SRL at 20 and 40 mg showed 6663.8% (P,0.0001)
and 70.467.4% (P,0.0001) inhibition of ZR-75 cells after 72 h
(Figure 2A and B). The inhibitory effect of SRL (20 mg/ml) on
proliferation of MCF-7 and ZR-75 cells was blocked by the
presence of TF-expressing aBSM (100 mg/ml) by 66.286
0.25%(P,0.0001) and 62.3362.0% (P,0.0001) respectively
and also by asialo-glycophorin A in MCF-7 cells, suggesting that
the growth inhibitory effect of SRL is mediated by its carbohy-
drate binding sites.
It was found that the presence of SRL caused weak inhibition of
proliferation of non-tumorigenic MCF-10A cells derived from
human fibrocystic mammary tissue and also of normal breast
epithelial HMEC cells. After 24, 48 and 72 h incubation with the
cells, SRL at 40 mg/ml showed inhibition of MCF-10A cell
proliferation by 2063.1% (P,0.0001), 31.561.0% (P,0.0001)
and 36.764.2% (P,0.0001) respectively. A similarly weak growth-
inhibitory effect of SRL (at 40 mg/ml) on HMECs was observed
after 48 h by 40.062.2% (P,0.0001) (Figure 3A and B). The
results indicate that in comparison to its strong growth inhibitory
effect in cancer cells, SRL has only weak effect on normal
epithelial cells. A four-time greater concentration of SRL is
required to produce similar growth inhibition in normal epithelial
cells in comparison with breast cancer cells (Figure 3).
SRL-mediated growth inhibition is a direct consequence
of its cell surface binding
SRL showed a strong and uniform binding to MCF-7 cells
(Figure 4A) where as weak and uneven binding to HMECs
(Figure 4B). Treatment with Sepharose-conjugated SRL demon-
strated a similar growth inhibitory effect on MCF-7 cells as the
unconjugated form (Figure 4C). This indicates that binding of
SRL to the cell surface is sufficient to trigger its growth inhibitory
effect.
Figure 6. SRL-mediated inhibition of cell proliferation is associated with induction of apoptosis. (A) MCF-7 cells were incubated without
or with SRL (20 mg/ml) in the presence or absence of inhibitors (50 mM) to caspase-8 (z-IETD), caspase- 9 (z-LEHD) or pan-caspases (z-VAD-(OMe) for
48 h before the caspase 3/7 activity was assessed. (B) MCF-7 cells were incubated with or without SRL (20 mg/mL) in the presence or absence 50 mM
pan-caspase inhibitor z-VAD-(OMe) for 48 h before the viable cells were assessed using Calcein AM. *P,0.05, **P,0.01, ***P,0.001. (C) MCF-10A and
MCF-7 cells were incubated without or with SRL (20 mg/ml) for 48 h before the caspase 3/7 activity was assessed by caspase 3/7 Glo assay. P = 0.5847
and ***P,0.001 respectively for MCF-10A and MCF-7 cells.
doi:10.1371/journal.pone.0110107.g006
Effect of SRL on Normal and Breast Cancer Cells
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SRL-mediated cell growth inhibition is associated with
induction of cell apoptosis
To assess whether the growth inhibitory effect of SRL is related
to induction of cell apoptosis, Annexin-V cell surface binding,
existence of sub-G1 population and cellular caspase-3/7 activity
were measured after cell treatment with SRL. MCF-7 cells treated
with SRL for 24, 36 and 48 h showed a gradual increase in
population of early apoptotic cells (Annexin V positive and PI
negative), by 5-fold, 13-fold and 21-fold, respectively, as compared
with untreated cells (Figure 5A). SRL treatment also increased the
cell sub-G1 population by 18, 23 and 39% after 24, 36 and 48 h
respectively in comparison with the control cells (Figure 5B).
Furthermore, treatment of MCF-7 cells with SRL (20 mg/ml) for
48 h resulted in 2.02-fold (P,0.001) increase in cellular caspase-3/
7 activity in comparison to the untreated cells (Figure 6A). On the
other hand, treatment with the same concentration of SRL
(20 mg/ml) for 48 h showed no significant effect on caspases-3/7
activity of non-tumorigenic MCF-10A cells (Fig. 6C). The
presence of inhibitors against caspase-8 or caspase-9 in the culture
showed to prevent SRL-induced caspase-3/7 activation. The
presence of pan-caspase inhibitor also showed to greatly reduce
the growth-inhibitory effect of SRL on MCF-7 cells (Figure 6B).
Activation of caspase-3 was further evidenced by images of
fluorescence microscopy, where SRL treated MCF-7 cells showed
positive staining for caspase-3 antibody (Figure 7A). All these
results collectively suggest that SRL-mediated cell growth inhibi-
tion is linked to its induction of cell apoptosis; an effect that
probably involves the activation of both the intrinsic and extrinsic
apoptotic pathways. This conclusion is supported by the increased
expressions of activated caspases-8, -9 and -3 and decreased
expressions of the inactive form of each caspase and also PARP
cleavage in a time-dependent manner after introduction of SRL.
The time-dependent increase in the expressions of FasL, FADD,
and truncation of Bid (Figure 7B) are also in keeping with the
likely involvement of both the intrinsic and extrinsic apoptotic
pathways in SRL-mediated apoptosis.
Figure 7. SRL induced apoptosis involves alteration of regulators. (A) Immunohistochemistry of MCF-7 cells after treatment with SRL. MCF-7
cells were grown on cover slips and incubated with 20 mg/ml SRL for 36 h followed by staining with FITC-SRL, Anti-active caspase-3 primary antibody
followed by pycoerythrin labelled secondary antibody and images were observed by fluorescence microscopy. (B) SRL-induced apoptosis in MCF-7
cells involves alteration of regulators in both the extrinsic and intrinsic apoptosis pathways. MCF-7 cells were incubated with SRL (20 mg/ml) for
different time intervals. At specific time intervals whole cell protein was obtained, separated by electrophoresis, blotted on to Immobilon
polyvinylidene difluoride membrane and probed with antibodies against FasL, FADD, tBID, PARP, pro-caspase-8, -9,-3 or active caspase-8, -9,-3. The
bands were visualized using chemiluminescence kit. The blots were stripped and reprobed for b-actin which was used as loading control.
doi:10.1371/journal.pone.0110107.g007
Effect of SRL on Normal and Breast Cancer Cells
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Discussion
This study shows that the presence of SRL caused strong
inhibition of proliferation in human breast cancer MCF-7 and
ZR-75 cells but a much lesser effect was observed in non-
tumorigenic human mammaryMCF-10A and normal HMEC
cells. The effect of SRL on cell growth inhibition is found to be
linked to SRL cell surface binding and subsequent induction of cell
apoptosis. SRL also shows strong binding to cancerous and
metastatic tissues but very weak binding to normal human breast
tissues.
Apoptosis or programmed cell death, which allows the
elimination of excessively produced, improperly developed or
genetically damaged cells [20], has been recognized as a possible
strategy for cancer therapy. Agents that have the ability to induce
apoptosis specifically in tumours have potential to be used in
antitumor therapy [21]. As most of the known chemotherapeutic
drugs designed to target neoplastic cells act both on cancer as well
as normal cells and invariably show undesirable side effects.
Hence, successful therapy should selectively eliminate the abnor-
mal cells while leaving all normal cells functionally undisturbed.
SRL that is shown in this study to induce apoptosis strongly in
cancerous cell than in normal cells would fit into the category of
such agents. The presence of caspase inhibitors against caspase-8
and -9 can effectively prevent SRL-induced cell apoptosis indicates
that SRL-mediated cell apoptosis, likely involves both the caspase-
8–regulated extrinsic pathway and the caspase-9–regulated
intrinsic pathway [22,23,24]. The extrinsic apoptosis pathway
involves ligation of the cell surface death receptors, through
adaptor molecules such as Fas and FADD, resulting in recruitment
of the initiator caspases-2, -8, or-10. The intrinsic apoptotic
pathway is triggered by signals within the cell that target
mitochondria, resulting in the release of apoptotic factors and
activation of initiator caspase-9. Both the extrinsic and intrinsic
pathways activate the ‘‘executioner’’ caspases (Caspase-3, 6 & -7)
[25,26]. The discovery that SRL-mediated cell apoptosis is
associated with increased cellular levels of FasL, FADD, BID
truncation, and increased PARP cleavage, all important regulators
in both extrinsic and intrinsic pathways, is in keeping with the
involvement of both extrinsic and intrinsic apoptotic pathways in
SRL-mediated apoptosis induction.
Various plant lectins that exhibit binding specificities toward
cancer-associated tumour glycans are valuable source for the
development of novel anti-cancer agents [27]. Particularly
interesting are the TF-binding lectins, which recognize the core
1 structure of O-linked mucin-type glycans that are commonly
over expressed by up to 90% of cancers [4]. As a fungal lectin that
binds specifically to the cancer-associated glycan and inhibits the
growth of human breast cancer cells but has substantially less effect
on normal epithelial cells, SRL has the potential to be developed
as an anti-cancer agent.
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